Global EpinephrineMarket, by Product Type (Auto-injector, Prefilled Syringes, and Ampoulesand Vials), by Application (Anaphylaxis, Cardiac Arrest, Superficial Bleeding,Respiratory Disorders, and Others), by Distribution Channel (Hospital Pharmacies,Retail Pharmacies, and Online Pharmacies) and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,040million in 2017, and is projected to exhibit a CAGR of 11.0% over the forecastperiod (2018 – 2026), as highlighted in a new report published by.
Significant number of novelpipeline products to augment the market growth the manufacturers are focused ondeveloping and commercializing innovative drugs and novel drug delivery systemsof therapeutic molecules to improve patient quality of life and to cater theclinical shortcomings of the commercially available products. According to theMayo Clinic, 2016, more than 200,000 cases of anaphylaxis occur annually in theU.S., indicating the higher number of potential patient pool in the region.Also, the World Allergy Organization, in 2015 estimated that up to two percentof the global population, accounting for 150 million people are expected toexperience anaphylaxis during their lifetime. In July 2018, INSYS Therapeutics,Inc. demonstrated the results of early clinical trial for its investigationalepinephrine nasal spray, as a potential needle-free, non-invasive, andeasy-to-use alternative to intramuscular injection for the treatment ofanaphylaxis. The investigators also highlighted the benefits of effectiveneedleless alternative delivery options showing rapid drug absorption. InAugust 2018, FDA granted Fast Track designation for the epinephrine nasalspray. Furthermore, in April 2018, Aquestive Therapeutics initiated the Phase-1clinical trials for its complex molecule programs- AQST-108 epinephrinemolecule for anaphylaxis, which is administered via sublingual route.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2401
Browse 36 Market Data Tables and34 Figures spread through 175 Pages and in-depth TOC on “Epinephrine Market”-Global Forecast to 2026, by Product Type (Auto-injector, Prefilled Syringes,and Ampoules and Vials), by Application (Anaphylaxis, Cardiac Arrest,Superficial Bleeding, Respiratory Disorders and Others), by DistributionChannel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and byRegion (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica)
The market players are focused onstrengthening strategic collaborations to provide products freely at retailoutlets, considering shortages in supply of competitors' epinephrine auto-injectors.For instance, in September 2018, Walgreens and Kaleo entered into partnershipunder which AUVI-Q would be available at all pharmacies across the U.S. Thisstep will aid in increasing accessibility of epinephrine auto-injector. Also,in July 2018, Adamis Pharmaceuticals announced that Sandoz, a Novartisdivision, bought the rights to market its epinephrine device, a pre-filled 0.3mg-dose syringe called Symjepi in the U.S. market. In 2015, Impax Laboratories,Inc. acquired Tower Holdings, Inc. including subsidiaries AmedraPharmaceuticals LLC. Amedra is manufacturer of the Adrenaclick (epinephrineinjection) auto-injector.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/epinephrine-market-2401
Key Takeaways of the EpinephrineMarket:
The global epinephrine market isexpected to exhibit a CAGR of 11.0% over the forecast period, owing to theapproval of cost-effective generic auto-injectors in the market, and strategicsupport of companies and government agencies for increasing generic epinephrineadoption.
Among product type, auto-injectorsegment held a dominant position in the epinephrine market in 2018, owing tothe wide use of the product in auto-injectable form due to ease ofadministration and rapid onset of action.
Among application, anaphylaxissegment held a dominant position in the epinephrine market in 2018, owing tohigh incidence rate of anaphylaxis due to consumption of food products such aspeanut or tree nut in children and increasing supplemental new drug applicationin infants.
Companies operating in the globalepinephrine market include Mylan N.V., Pfizer, Inc., Teva PharmaceuticalsIndustries Ltd., Impax Laboratories, Inc., Kaleo, Inc., Adamis PharmaceuticalsCorporation, Bausch Health Companies, ALK- Abello A/S
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2401
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
